Cargando…

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

BACKGROUND AND AIMS: Safety and efficacy of budesonide multimatrix, an oral extended-release second-generation corticosteroid designed for targeted delivery throughout the colon, were examined for induction of remission in patients with mild to moderate ulcerative colitis refractory to baseline mesa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubin, David T., Cohen, Russell D., Sandborn, William J., Lichtenstein, Gary R., Axler, Jeffrey, Riddell, Robert H., Zhu, Cindy, Barrett, Andrew C., Bortey, Enoch, Forbes, William P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881669/ https://www.ncbi.nlm.nih.gov/pubmed/28333362 http://dx.doi.org/10.1093/ecco-jcc/jjx032

Ejemplares similares

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis
por: Cuffari, Carmen, et al.
Publicado: (2016)

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
por: Kanazawa, Mimari, et al.
Publicado: (2022)

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
por: Rubin, David T., et al.
Publicado: (2015)

Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study
por: Croft, Nicholas Michael, et al.
Publicado: (2023)

The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007)

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
por: Lichtenstein, Gary R.
Publicado: (2015)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach
por: Christophi, George P, et al.
Publicado: (2016)

Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
por: Minagawa, Yuki, et al.
Publicado: (2022)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
por: Willian, Mary Kaye, et al.
Publicado: (2018)

Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
por: Santos, Yurianna, et al.
Publicado: (2023)

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study
por: Yarlas, Aaron, et al.
Publicado: (2018)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis
por: Okoro, Kelechukwu U., et al.
Publicado: (2018)

Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies
por: Bosworth, Brian P., et al.
Publicado: (2016)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
por: Doherty, Glen A, et al.
Publicado: (2009)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis
por: Moran, Christopher J., et al.
Publicado: (2018)

A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions
por: Hirono, Haruka, et al.
Publicado: (2018)

Urine Discoloration After Voiding in a Boy With Ulcerative Colitis Using Mesalamine
por: Zeef, Dagmar, et al.
Publicado: (2022)

Lack of effect of methotrexate in budesonide-refractory collagenous colitis
por: Münch, Andreas, et al.
Publicado: (2013)

Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis
por: Shimodate, Yuichi, et al.
Publicado: (2011)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013)

Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach
por: Ren, Peng-wei, et al.
Publicado: (2017)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Fulminant organizing pneumonia in a patient with ulcerative colitis on mesalamine and infliximab: striving to identify the cause!
por: Gomes, Lídia, et al.
Publicado: (2023)

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
por: Iborra, Marisa, et al.
Publicado: (2014)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
por: Yarlas, Aaron, et al.
Publicado: (2021)

Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report
por: Perez-Colon, Elimarys, et al.
Publicado: (2011)

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
por: Winter, Harland S., et al.
Publicado: (2014)

The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis
por: Tian, Chunying, et al.
Publicado: (2020)

Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment
por: Dai, Liang, et al.
Publicado: (2021)

19144 Effect of Mesalamine on Metabolic Syndrome risk factors in Ulcerative Colitis Patients: A Retrospective study
por: Castillo, Eliseo, et al.
Publicado: (2021)

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi, Giovanni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p4rgpnsl67164q6htacdbrov0v